))
Protecting the product of innovation: IP and commercialization in cell and gene therapies
Manage episode 355403969 series 3291201
Content provided by CCRM. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by CCRM or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Featuring:
Mark Taylor, Director of Commercialization, University Health Network
Dr. Irja Elliott Donaghue Technical & IP Specialist and Patent Agent, Notch Therapeutics
In the past, there was little evidence to challenge the idea that if a therapeutics developer did not hold a patent, it did not have anything to commercialize. In this episode, guests outline how the regenerative medicine industry changed that, proving the belief to be outdated, with some innovation being better protected by developers taking a “trade secrets” approach. Listen to hear guests examine intellectual property and commercialization issues in cell and gene therapies, with discussion of the complexities around the long-running patent battle over CRISPR technology, which has garnered international headlines in the last couple of years. Also discussed is how to protect and publish research, and the importance of having discussions with commercialization teams early in the technology development process.
Thanks for listening to Commercializing Living Therapies with CCRM. Spread the word about this episode by taking a screen cap on your device and posting it to social media using the hashtag #CCRMpodcast. Please leave us a review on your favourite streaming service. Find more episodes at ccrm.ca/podcast.
18 episodes
Share
